Becton Dickinson — Aug 6, 2026 release

• Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion • Company updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance FRANKLIN LAKES, NJ (August 6, 2026) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026. "We delivered a strong third quarter, with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD. "Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence. We remain focused on disciplined execution, advancing our key growth platforms, expanding margins and allocating capital strategically to drive sustainable growth and long-term shareholder value." Recent Business Highlights • Medical Essentials: • Awarded a Vizient Innovative Technology contract for the BD® CentroVena One™ Insertion System , validating CentroVena One ™ Insertion System as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety. • BioPharma Systems: • Anno